Clinical Edge Journal Scan

Atopic dermatitis increases the risk for food allergy, food sensitivity, challenge-proven food allergy, and vice versa


 

Key clinical point: Patients with atopic dermatitis (AD) have an increased risk of developing food allergy (FA), food sensitivity (FS), and challenge-proven food allergy (CPFA), and vice versa.

Major finding: AD was significantly associated with an increased risk for FS (pooled odds ratio [pOR] 4.17; 95% CI 3.03-5.75), FA (pOR 3.91; 95% CI 3.44-4.45), and CPFA (pOR 4.99; 95% CI 2.20-11.35). A significantly increased risk for AD was observed in individuals with FS (pOR 3.92; 95% CI,2.88-5.33), FA (pOR 4.06; 95% CI 3.54-4.65), and CPFA (pOR 4.93; 95% CI 2.74-8.84).

Study details: Findings are from a meta-analysis of 465 studies involving patients with AD (n = 225,568); reference individuals without AD (n = 1,128,322); individuals with FS, FA, and CPFA (n = 1,357,793); and reference individuals without FS, FA, and CPFA (n = 1,244,596).

Disclosures: This study did not receive any funding. Some authors declared serving as advisors, speakers, or consultants for or receiving speaking or consulting fees from various sources.

Source: Christensen MO et al. Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2023 (Jan 25). Doi: 10.1111/jdv.18919

Recommended Reading

Dupilumab shows rapid and sustained efficacy and favorable safety in erythrodermic atopic dermatitis
MDedge Dermatology
Risk for atopic dermatitis in children alters with the mode of delivery
MDedge Dermatology
Tralokinumab counters difficult-to-treat moderate-to-severe atopic dermatitis
MDedge Dermatology
Tralokinumab counters difficult-to-treat moderate-to-severe atopic dermatitis
MDedge Dermatology
Dupilumab a favorable treatment option for moderate-to-severe atopic dermatitis
MDedge Dermatology
Atopic dermatitis with hand eczema: Upadacitinib is safe and effective in daily practice
MDedge Dermatology
A probiotic reduces disease severity in children and adolescents with atopic dermatitis
MDedge Dermatology
Dupilumab offers long-term drug survival in moderate-to-severe atopic dermatitis in a real-world setting
MDedge Dermatology
IgE levels may guide diagnosis and management in children hospitalized for atopic dermatitis exacerbation
MDedge Dermatology
Atopic dermatitis: Association of itch with patient- vs physician-reported outcomes
MDedge Dermatology